A low testosterone level in a man with obesity - what to advise based on current evidence

Author(s):  
Richard Quinton
2009 ◽  
Vol 6 (3) ◽  
pp. 39-42 ◽  
Author(s):  
L V Savel'eva ◽  
R V Rozhivanov ◽  
B O Shurdumova ◽  
V V Fadeev

Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.


2018 ◽  
Vol 27 (12) ◽  
pp. 3549-3554 ◽  
Author(s):  
Mun Hee Choi ◽  
Tae Sung Lim ◽  
Bok Seon Yoon ◽  
Keoung Sun Son ◽  
Ji Man Hong ◽  
...  

2020 ◽  
Vol 70 (696) ◽  
pp. 364-365
Author(s):  
Ahmed Al-Sharefi ◽  
Scott Wilkes ◽  
Channa N Jayasena ◽  
Richard Quinton

2011 ◽  
Vol 22 (6) ◽  
pp. e133-e136 ◽  
Author(s):  
Xiaorong Hu ◽  
Li Rui ◽  
Tongjian Zhu ◽  
Hao Xia ◽  
Xinhong Yang ◽  
...  

2010 ◽  
Vol 210 (1) ◽  
pp. 232-236 ◽  
Author(s):  
Masahiro Akishita ◽  
Masayoshi Hashimoto ◽  
Yumiko Ohike ◽  
Sumito Ogawa ◽  
Katsuya Iijima ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
G. Hackett ◽  
M. Kirby ◽  
A. J. Sinclair

Low levels of testosterone are manifested by erectile dysfunction, reduced sexual desire, and loss of morning erections with increasing numbers of men are being diagnosed and require treatment. The prevalence rates of testosterone deficiency vary according to different studies but may be as high as 40% in populations of patients with type 2 diabetes. There is increasing evidence that testosterone deficiency is associated with increased cardiovascular and all-cause mortality. Screening for low testosterone is recommended in a number of high risk groups including those with type 2 diabetes and metabolic syndrome. There are recent data to suggest that testosterone replacement therapy may reduce cardiovascular mortality as well as improving multiple surrogate markers for cardiovascular events. Specific clinical trials of testosterone replacement therapy are needed in selected populations but in the meantime we must treat patients based on the best current evidence.


2013 ◽  
pp. 5-14
Author(s):  
Hai Thuy Nguyen

Testosterone is vital hormone for men’s health and a keyplayer in glucose homeostasis, lipid metabolism, and cardiovascular pathology. Testosterone deficiency is associated with age, many chronic health conditions and other metabolic disorders. There is strong evidence that a low testosterone level has a high prevalence in men with metabolic syndrome. Many components of metabolic syndrome are adversely affected especially in relation to cardiovascular risk in the presence of hypogonadism.Testosterone deficiency is a risk factor in itself for the subsequent development of the metabolic syndrome. The hypothesis suggests that low testosterone as a result of high aromatase activity leads to a cycle which promotes increasing adipocyte number and fat deposition which gradually leads to a lower testosterone level. The hypogonadal-obesity-adipocytokine hypothesis explains why the body cannot respond to low testosterone levels by a compensatory production of the hormone. The interventional studies have shown that testosterone administration on hypogonadal men with metabolic syndrome has beneficial effects. These benefits have not only found that hypogonadal symptoms such as sexual function improve, but key metabolic markers also improve. It must also not be forgotten that testosterone replacement therapy in hypogonadal men with metabolic syndrome can have a major impact on the patient’s quality of life and well-being. Key words: testosterone, metabolic syndrome.


Sign in / Sign up

Export Citation Format

Share Document